USANA Health Sciences (NYSE:USNA - Get Free Report) released its earnings results on Tuesday. The company reported $0.73 EPS for the quarter, topping analysts' consensus estimates of $0.70 by $0.03, Zacks reports. The business had revenue of $249.54 million for the quarter, compared to the consensus estimate of $243.08 million. USANA Health Sciences had a net margin of 6.30% and a return on equity of 10.64%. During the same period in the previous year, the firm earned $0.86 EPS. USANA Health Sciences updated its FY 2025 guidance to 2.350-3.000 EPS.
USANA Health Sciences Stock Up 1.3 %
USNA stock opened at $24.13 on Wednesday. The company has a 50 day moving average of $28.16 and a two-hundred day moving average of $33.38. The company has a market cap of $456.20 million, a price-to-earnings ratio of 8.53, a PEG ratio of 0.93 and a beta of 1.00. USANA Health Sciences has a 12-month low of $23.10 and a 12-month high of $49.78.
Analysts Set New Price Targets
USNA has been the subject of several research analyst reports. StockNews.com downgraded shares of USANA Health Sciences from a "strong-buy" rating to a "buy" rating in a research report on Friday, February 14th. DA Davidson reduced their target price on USANA Health Sciences from $38.00 to $36.00 and set a "neutral" rating for the company in a report on Thursday, February 27th. Finally, Sidoti lowered USANA Health Sciences from a "strong-buy" rating to a "hold" rating in a research report on Tuesday, February 18th.
Get Our Latest Analysis on USANA Health Sciences
Insider Activity
In other news, CEO Jim Brown sold 5,000 shares of the stock in a transaction on Monday, March 3rd. The shares were sold at an average price of $29.47, for a total transaction of $147,350.00. Following the transaction, the chief executive officer now owns 15,716 shares in the company, valued at $463,150.52. This represents a 24.14 % decrease in their position. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, insider Joshua Foukas sold 5,732 shares of USANA Health Sciences stock in a transaction on Wednesday, March 12th. The shares were sold at an average price of $32.54, for a total transaction of $186,519.28. The disclosure for this sale can be found here. Insiders have sold a total of 15,920 shares of company stock worth $500,285 in the last ninety days. Corporate insiders own 0.63% of the company's stock.
USANA Health Sciences Company Profile
(
Get Free Report)
USANA Health Sciences, Inc develops, manufactures, and sells science-based nutritional, personal care, and skincare products in the Asia Pacific, the Americas, and Europe. The company offers USANA nutritional products that comprise essentials/CellSentials, such as vitamin and mineral supplements that provide a foundation of total body nutrition for various age groups; optimizers consisting of targeted supplements that are designed to meet cardiovascular, skeletal/structural, and digestive health needs; and food that include meal replacement shakes, snack bars, and other related products.
See Also
Before you consider USANA Health Sciences, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and USANA Health Sciences wasn't on the list.
While USANA Health Sciences currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Enter your email address and we'll send you MarketBeat's list of ten stocks that are set to soar in Spring 2025, despite the threat of tariffs and other economic uncertainty. These ten stocks are incredibly resilient and are likely to thrive in any economic environment.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
